NCT06364098View on ClinicalTrials.gov

Comparative Study Between the Roles of Intrauterine Misoprostol Versus the Sublingual Route for Prevention of Postpartum Blood Loss in Elective Cesarean Sections

PHASE1CompletedINTERVENTIONAL

Enrollment

192

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions

Postpartum Hemorrhage

Interventions

DRUG

Misoprostol

400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion

Trial Locations (1)

11956

Faculty of medicine, Kasr Alainy, Cairo

All Listed Sponsors

lead

Cairo University

OTHER

NCT06364098 - Comparative Study Between the Roles of Intrauterine Misoprostol Versus the Sublingual Route for Prevention of Postpartum Blood Loss in Elective Cesarean Sections | Biotech Hunter | Biotech Hunter